Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Head and Neck Squamous Cell Carcinoma: early-phase trial registry
71 of 125 indexed Head and Neck Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #95 of 28,707 conditions by registered trial count.
125 US clinical trials · 71 currently recruiting · #95 of 28,707 conditions by registered trial count
Head and Neck Squamous Cell Carcinoma: 125 US clinical trials tracked, 71 recruiting.
Head and Neck Squamous Cell Carcinoma is the subject of 125 registered US clinical trials on ClinicalTrials.gov, 71 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 111 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 5 of these trials.
Enrollment posture brief
Registry condition head-and-neck-squamous-cell-carcinoma
OPEN 71 | RECR 57% | LATE 4 | EARLY 111 | RANK #95 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Survivorship (57% recruiting · 37 trials)
Head and Neck Squamous Cell Carcinoma lists 71 open slots (57% of 125 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Head and Neck Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Head and Neck Squamous Cell Carcinoma is recruiting above its size-band peers.
71 of 125 indexed trials (56.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Head and Neck Squamous Cell Carcinoma trials is spread across many organizations.
AstraZeneca accounts for 5 of 125 trials (4%). 89 distinct sponsors appear on at least one study for this condition label.
-
Most Head and Neck Squamous Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 61 among the 125 trials that report a genuine target (sentinel values excluded). 84 of those (67.2%) plan for fewer than 100 participants.
-
Head and Neck Squamous Cell Carcinoma research is mostly interventional.
122 interventional and 3 observational studies make up this index (97.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
125 total, page 1 of 3
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
Medical University of South Carolina
NCT05793151
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
NCT03526835
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
AbbVie
NCT05005403
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Merus B.V.
NCT06496178
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Tempus AI
NCT06163534
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
NCT06525220
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune
NCT05983432
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics
NCT05107674
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT04429542
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology
NCT03556228
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Alliance for Clinical Trials in Oncology
NCT06992427
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT06305247
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
NCT04564989
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences
NCT07109726
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics
NCT05902988
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
ECOG-ACRIN Cancer Research Group
NCT02734537
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics
NCT06747585
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine
NCT06022029
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Epkin
NCT06789172
Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality
Thomas Jefferson University
NCT05031910
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
TiumBio Co.
NCT05784688
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies
NCT06047379
Study of NEO-201 in Solid Tumors Expansion Cohorts
Precision Biologics
NCT03476681
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
University of Texas Southwestern Medical Center
NCT05576974
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Emory University
NCT06662058
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
NCT07216105
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
AstraZeneca
NCT06535607
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
M.D. Anderson Cancer Center
NCT05674396
Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy
Covenant Health Cancer Center
NCT06183268
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
NCT06532279
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT06999187
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Providence Health & Services
NCT05913388
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics
NCT06778863
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Portage Biotech
NCT04969315
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Boehringer Ingelheim
NCT06806852
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad
NCT04291105
Study of CHS-114 in Participants With Advanced Solid Tumors
Coherus Oncology
NCT05635643
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
NCT06150664
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT06147037
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Roswell Park Cancer Institute
NCT06995508
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
University of Maryland, Baltimore
NCT06088381
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Eben Rosenthal
NCT05747625
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT07115043
A Study of VET3-TGI in Patients With Solid Tumors
KaliVir Immunotherapeutics
NCT06444815
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
Vanderbilt-Ingram Cancer Center
NCT05996432
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
NCT05877599
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT03740256
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
NCT06980038
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
H. Lee Moffitt Cancer Center and Research Institute
NCT06597565
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
NCT05945875
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 68 |
| Phase 2 | 43 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Head and Neck Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Head and Neck Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Head and Neck Squamous Cell Carcinoma page
125 registered trials, 71 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 71 Head and Neck Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Head and Neck Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Head and Neck Squamous Cell Carcinoma condition card totals 125 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.